Head to Head Contrast: Intellia Therapeutics (NTLA) & Its Competitors
Intellia Therapeutics (NASDAQ: NTLA) is one of 199 public companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its peers? We will compare Intellia Therapeutics to related businesses based on the strength of its valuation, earnings, institutional ownership, analyst recommendations, profitability, dividends and risk.
Institutional & Insider Ownership
47.8% of Intellia Therapeutics shares are held by institutional investors. Comparatively, 46.9% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 12.8% of Intellia Therapeutics shares are held by insiders. Comparatively, 13.8% of shares of all “Biotechnology & Medical Research” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Earnings and Valuation
This table compares Intellia Therapeutics and its peers gross revenue, earnings per share and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Intellia Therapeutics||$16.48 million||-$31.63 million||-14.06|
|Intellia Therapeutics Competitors||$220.75 million||-$39.68 million||3.32|
Intellia Therapeutics’ peers have higher revenue, but lower earnings than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
This table compares Intellia Therapeutics and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Intellia Therapeutics Competitors||-3,997.85%||-118.99%||-43.92%|
Risk and Volatility
Intellia Therapeutics has a beta of 2.93, suggesting that its share price is 193% more volatile than the S&P 500. Comparatively, Intellia Therapeutics’ peers have a beta of 1.62, suggesting that their average share price is 62% more volatile than the S&P 500.
This is a summary of recent ratings and target prices for Intellia Therapeutics and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Intellia Therapeutics Competitors||484||2292||6259||120||2.66|
Intellia Therapeutics presently has a consensus price target of $30.17, indicating a potential upside of 37.50%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 2.88%. Given Intellia Therapeutics’ higher possible upside, equities research analysts clearly believe Intellia Therapeutics is more favorable than its peers.
Intellia Therapeutics beats its peers on 7 of the 12 factors compared.
About Intellia Therapeutics
Intellia Therapeutics, Inc. is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene. The guide RNA sequence recognizes and directs the Cas9 to a specific target deoxyribonucleic acid (DNA) sequence. The Company’s sentinel in vivo programs focus on the use of Lipid Nanoparticle (LNPs) for delivery of the CRISPR/Cas9 complex to the liver. The Company’s division, eXtellia Therapeutics, is focused on the application of CRISPR/Cas9 genome editing in the fields of immuno-oncology and autoimmune and inflammatory diseases. The Company’s subsidiary is Intellia Securities Corp. As of September 30, 2016, the Company had not generated any revenue.
Receive News & Ratings for Intellia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.